Group 1 - The article emphasizes that the market may be overlooking defensive healthcare stocks, particularly mentioning Bristol Myers Squibb (BMY) as having experienced a shift in trading momentum [1] - The author expresses a belief that macro trends significantly influence asset prices and investor behavior, highlighting the importance of understanding these dynamics for investment strategies [1] - The article aims to foster a community of investors who share insights and ideas to enhance long-term investment confidence [1] Group 2 - The author has a professional background in asset management, focusing on equity analysis, macroeconomics, and risk-managed portfolio construction [1] - The article discusses the author's experience navigating various market conditions over the past decade, indicating a deep understanding of market dynamics [1]

Group 1 - The cash deal aims to enhance the French drugmaker's immunization portfolio following setbacks in clinical trials [1]

Asian markets are mostly higher after the U.S. benchmark S&P 500 closed at another record high following a report that the U.S. economy grew at a 4.3% annual rate in July to SeptemberA person walks in front of a chart showing Japan's Nikkei index at a securities firm Friday, Dec. 19, 2025, in Tokyo. (AP Photo/Eugene Hoshiko)HONG KONG -- Asian markets mostly advanced Wednesday after the benchmark S & P 500 closed at another record high following a report that the U.S. economy grew at an unexpectedly strong 4 ...

Group 1 - UiPath Inc. will join the S&P Midcap 400, replacing Synovus Financial Corp., effective January 2, 2026, leading to a 6.8% increase in shares to $17.05 in after-hours trading [1] - Agios Pharmaceuticals Inc. received FDA approval for AQVESME™ for treating anemia in adults with alpha- or beta-thalassemia, but shares fell 1.4% to $24.59 [1] - Can Fite Biopharma announced a 1-for-3,000 reverse share split, resulting in a 28.8% drop in shares to $0.17 in after-hours trading [1] - Citius Pharmaceuticals reported a quarterly loss of 11 cents per share, better than the expected loss of 43 cents, causing shares to surge 22.1% to $1.27 [1] - Ramaco Resources announced a $100 million stock repurchase plan, leading to a 7.1% increase in shares to $18.09 in after-hours trading [1]

NEW YORK (AP) — Wall Street closed higher and reached more records Wednesday on a holiday-shortened trading day. The S&P 500 index rose 22.26 points, or 0.3%, to 6,932.05. The Dow Jones Industrial Average added 288.75, or 0.6%, to close at 48,731.16, and the Nasdaq composite added 51.46, or 0.2%, to 23,613.31 Trading was extremely light as markets closed early for Christmas Eve and will be closed for Christmas Thursday. Roughly 1.8 billion shares traded on the New York Stock Exchange on Wednesday, which ...

Benchmark equity indices Sensex and Nifty rallied in early trade on Wednesday (December 24, 2025), tracking a positive trend in global markets and consistent buying by domestic institutional investors.The 30-share BSE Sensex climbed 115.8 points to 85,640.64 in early trade. The 50-share NSE Nifty went up by 40.7 points to 26,217.85.From the 30-Sensex firms, Bajaj Finance, NTPC, Trent, Bharat Electronics, Adani Ports and Eternal were among the gainers.However, Tech Mahindra, Infosys, HCL Tech and Sun Pharma ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Telix Pharmaceuticals Ltd. securities between February 21, 2025, and August 28, 2025, about the January 9, 2026, deadline to become a lead plaintiff in a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Telix securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the firm or visiting their website [3][6]. - The lawsuit alleges that defendants made materially false and misleading statements regarding Telix's progress in prostate cancer therapeutic candidates and the quality of its supply chain, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4].

Core Insights - Global pharmaceutical companies Eli Lilly and Novo Nordisk are competing to establish their dominance in India's rapidly growing obesity drug market before the introduction of cheaper generic alternatives in March next year [1] Company Focus - Eli Lilly and Novo Nordisk are recognized as major players in the obesity drug sector, indicating their significant investment and strategic initiatives aimed at capturing market share in India [1]

Investment Thesis - The investment thesis regarding Teva Pharmaceutical has materialized, with the stock price increasing from approximately $16.50-$17.00 to over $31.50 [1] Company Overview - Teva Pharmaceutical is a significant player in the pharmaceutical industry, and its stock performance indicates a successful investment opportunity [1] Research and Analysis - Allka Research has over two decades of experience in identifying undervalued assets across various sectors, including pharmaceuticals [2] - The firm aims to simplify investment strategies and provide substantial returns to its clients, contributing to informed investment decisions [2]

for more in its first ever GLP1 pill. Guggenheim partner Sheamus Fernandez joins us now. He is the firm's managing director and pharma analyst.Sheamus, great to have you with us. >> Nice to see you. >> Does this change the competitive landscape at all with Eli Liy's or four coming on um and and some other competitors coming, you know, down the pike.>> It's a great question. I mean, I think it doesn't necessarily change the competitive landscape that dramatically. Um but it does give Novo an opportunity to g ...